SISCAPA Assay Technologies
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.
Waters Licenses Mass Spec Standardization Tech From SISCAPA
Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.